Medical Tips Online

  •  

Researchers report game-changing advance in stem cell science

November 14, 2019

By adding other chemicals, the scientists are able to then direct the precursor cells to differentiate into different types of mature neurons, "which means you can explore potential clinical applications for a wide range of neurodegenerative diseases," said Zhang. "You can generate neurons for specific conditions like amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), Parkinson's disease or, in the case of my particular research area, eye-specific neurons that are lost i...

Genentech's Lucentis Phase III trials in DME meets primary endpoints

November 13, 2019

Key secondary endpoints met statistical significance and included average eye chart reading scores over time and changes in retinal swelling. Safety A preliminary analysis of the 24-month data from the RIDE study showed an ocular and systemic safety profile consistent with previous Lucentis Phase III trials. Common ocular adverse events that occurred more frequently in the Lucentis dosing groups than in the sham injection group included conjunctival hemorrhage, eye pain, eye irritation, vitreous...

BioTime to merge Glycosan with OrthoCyte

November 12, 2019

Historically speaking, the complexity of cell types obtainable from hES and iPS cells has also been a challenge. Human therapeutic products require a high degree of purity to meet the hurdles of regulatory approval. BioTime's ACTCellerate?? technology was invented as a means of generating over 140 diverse human cell types from hES or iPS cells in a scalable and highly purified state. These diverse cell lines have applications in basic laboratory research and are being marketed for that purpose....

Promedior initiates Phase 1b clinical study of PRM-151 in patients with IPF

November 11, 2019

"We are excited to advance PRM-151 into this clinical study in patients with IPF, as we believe that PRM-151 represents a novel and powerful first-in-class agent to prevent and treat a wide variety of serious fibrotic diseases, including IPF," said Dominick Colangelo, President and Chief Executive Officer of Promedior. "This is the third clinical trial for our anti-fibrotic platform, and builds upon our recently completed Phase 1a study in which we observed positive effects of PRM...

BioTime announces acquisition of CTI assets

November 10, 2019

"Our acquisition of the assets of CTI is indicative of our plan to assemble a core of stem cell and related manufacturing technologies capable of enabling our development of a wide array of therapeutic products in the emerging field of regenerative medicine," said Michael D. West, Ph.D., President and Chief Executive Officer of BioTime, Inc. "We look forward to advancing Dr. Ruoslahti's technology and welcome Dr. Joseph Wagner to the BioTime team." Dr. Joseph Wagner, Cell Tar...